Sandoz | search
Click here to view Sandoz news from 60+ newspapers.
Bookmark or Share- SandozSandoz is a global leader in generic and biosimilar medicines, dedicated to improving healthcare.
- 241030 Q3 9M sales presentation - investors-sandoz-com.cms.sandoz.com• Continued uptake of Sandoz Hyrimoz® and unbranded adalimumab-adaz 1. Based on IQVIA weekly total scripts (TRx) for week ending October 18, 2024, Sandoz share including scripts from Cordavis private label 2. IQVIA implemented “data replacement” methodology for Cordavis private label product volumes in September 2024
- Pioneering access for patients - investors-sandoz-com.cms.sandoz.comSandoz delivered solid financial results in the first half of 2024, meeting key milestones in our biosimilar business and progressing on our journey as a standalone company. The momentum in the business continues, as demonstrated by strong double-digit growth in biosimilars and a positive contribution by all three regions. Net sales reached USD
- Sandoz 2023 Integrated Annual ReportSandoz today is the leading global provider of off-patent medicines (biosimilars and generics), which account for approximately 80% of medicines used worldwide at a fraction of the total cost.
- Sandoz Customer Connect™Login to Sandoz Customer Connect™ Email Address: Password: Login; Forgot Password? > New to Sandoz? Contact Us; FAQ; Terms of Use; Privacy Policy; Returns Policy
More
